The multi-million dollar deal will see the company help deliver GSK's new biotech facility in Marburg, Germany. The developmebt will produce bulk recombinant proteins used in meningitis vaccines.
The contract includes detailed design, procurement and subcontracting services, expediting and inspection of process equipment and packages, construction management, coordination of commissioning, engineering follow-up during construction, design qualification, as well as the overall project management.
-- Advertisement --
An outline design for the facility has already been completed by Wood's Environment & Infrastructure Solutions business. Completion of commissioning is scheduled for July 2019.
Robin Watson, Wood's chief executive, said: "This new contract recognises GSK's confidence in our global capabilities and broad, innovative solutions, based on our strong track record of supporting them for over a decade in locations including Singapore, Belgium, Italy, France and Hungary.
"Our focus is applying our vast knowledge and expertise in designing and constructing vaccines facilities, to ensure the safe and efficient delivery of this significant project in Germany. We look forward to working in partnership with GSK on this contract, which is another significant step towards delivering our growth ambitions in the pharmaceuticals sector."
(LM)
